Standardized methods for the production of high specific-activity zirconium-89

Nuclear Medicine and Biology

Volumn 36, Issue 7, 2009, Pages 729-739

  Holland, Jason P ^a   Sheh, Yiauchung ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cyclotron targetry; Desferrioxamine; Hydroxamates; Positron emission tomography; Radiopharmaceuticals; Zirconium 89

Indexed keywords

DEFEROXAMINE MESYLATE; HYDROXAMIC ACID; MONOCLONAL ANTIBODY; RADIOISOTOPE; RESIN; UNCLASSIFIED DRUG; YTTRIUM; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE; ZIRCONIUM TETRACHLORIDE;

ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CYCLOTRON; DRUG EXCRETION; DRUG ISOLATION; DRUG PURITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; IMAGE ANALYSIS; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTON RADIATION; RADIATION ENERGY; RADIOISOTOPE DECAY; ROOM TEMPERATURE; STANDARDIZATION; TIME;

ANIMALS; BENCHMARKING; CHELATING AGENTS; CYCLOTRONS; DEFEROXAMINE; HUMANS; HYDROXAMIC ACIDS; LIGANDS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; ZIRCONIUM;

EID: 69249216426     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.05.007     Document Type: Article

References (47)

1. Nayak T.K., and Brechbiel M.W. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjugate Chem (2009) 10.1021/bc800299f
2. Boswell C.A., and Brechbiel M.W. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34 (2007) 757-778
3. van Dongen G.A.M.S., Visser G.W.M., Lub-de Hooge M.N., de Vries E.G., and Perk L.R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 12 (2007) 1379-1389
4. Wu A.M. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50 (2009) 2-5
5. 88Y reactions up to 40 MeV. Phys Rev C 38 (1988) 1624-1637
6. Hinrichsen P.F. Decay of 78.4 hour zirconium-89. Nucl Phys A 118 (1968) 538-544
7. 89Zr-labeled monoclonal antibodies. J. Nucl Med 44 (2003) 1271-1281
8. Lewis J.S., Singh R.K., and Welch M.J. Long lived and unconventional PET radionuclides. In: Pomper M.G., and Gelovani J.G. (Eds). Chapter 18 in molecular imaging in oncology (2009), Informa Healthcare, New York (N.Y.). 978-0-8493-7417-3 283-292
9. Hohn A., Zimmermann K., Schaub E., Hirzel W., Schubiger P.A., and Schibli R. Production and separation of "non-standard" PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Quarterly J Nucl Med Mol Imaging 52 (2008) 145-150
10. Inarida M., and Shimamura A. Separation of carrier-free zirconium from yttrium target. Rikagaku Kenkyusho Hokoku 46 (1970) 63-65
11. 89Zr for antibody labelling and positron tomography. J Labeled Compd Radiopharm 23 (1986) 1296-1297
12. DeJesus O.T., and Nickles R.J. Production and purification of 89Zr, a potential PET antibody label. Appl Radiat Isotopes 41 (1990) 789-790
13. 90,91m,92mNb in alpha-particle activated yttrium and their separation by HDEHP. Appl Radiat Isotopes 48 (1997) 883-886
14. 89Zr in proton induced reactions on yttrium. J Radioanal Nucl Chem 274 (2007) 45-52
15. 52mMn generator based on a hydroxamate resin. Int J Appl Radiat Isotopes 34 (1983) 883-886
16. Fadeeva V.I., Tikhomirova T.I., Yuferova I.B., and Kudryavtsev G.V. Preparation, properties and analytical applications of silica with chemically grafted hydroxamic acid groups. Anal Chim Acta 219 (1989) 201
17. 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isotopes 45 (1994) 1143-1147
18. Zweit J., Downey S., and Sharma H.L. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isotopes 42 (1991) 199-201
19. Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med 49 (2009) 1114-1131
20. Yoo J., Tang L., Perkins Todd A., Rowland Douglas J., Laforest R., Lewis Jason S., et al. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol 32 (2005) 891-897
21. Meijs W.E., Herscheid J.D.M., Haisma H.J., and Pinedo H.M. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isotopes 43 (1992) 1443-1447
22. Kim J.S., Lee J.S., Im K.C., Kim S.J., Kim S.Y., Lee D.S., et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med 48 (2007) 1527-1535
23. Tseng J.C., Zanzonico P.B., Levin B., Finn R., Larson S.M., and Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 47 (2006) 1136-1143
24. Mealey J. Turn-over of carrier-free zirconium-89 in man. Nature 179 (1957) 673-674
25. Mealey Jr. J. Application of positron-emitting zirconium-89 for potential use in brain tumor localization. Surg Forum 9 (1958) 718-721
26. Meijs W.E., Haisma H.J., Van der Schors R., Wijbrandts R., Van den Oever K., Klok R.P., et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol 23 (1996) 439-448
27. Meijs W.E., Haisma H.J., Klok R.P., van Gog F.B., Kievit E., Pinedo H.M., et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 38 (1997) 112-118
28. Verel I., Visser G.W.M., Boerman O., Van Eerd J., Finn R., Boellaard R., et al. Long-lived positron emitters Zirconium-89 and Iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharmaceut 18 (2003) 655-661
29. 90Y-labeled monoclonal antibodies in Xenograft-bearing nude mice. J Nucl Med 44 (2003) 1663-1670
30. Verel I., Visser G.W.M., Vosjan M.J.W.D., Finn R., Boellaard R., and Van Dongen G.A.M.S. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 31 (2004) 1645-1652
31. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharmaceut 19 (2004) 155-163
32. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody Cetuximab. J Nucl Med 46 (2005) 1898-1906
33. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 1337-1345
34. Börjesson P.K.E., Jauw Y.W.S., Boellaard R., de Bree R., Comans E.F.I., Roos J.C., et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 12 (2006) 2133-2140
35. Nagengast W.B., de Vries E.G., Hospers G.A., Mulder N.H., de Jong J.R., Hollema H., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48 (2007) 1313-1319
36. Perk L.R., Stigter-van Walsum M., Visser G.W.M., Kloet R.W., Vosjan M.J.W.D., Leemans C.R., et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 35 (2008) 1857-1867
37. Perk L.R., Visser G.W.M., Budde M., Vosjan M.J.W.D., Jurek P., Kiefer G.E., et al. Facile radiolabeling of monoclonal antibodies and other proteins with zirconium-89 or gallium-68 for PET imaging using p-isothiocyanatobenzyl-desferrioxamine. Nature Protocols (2008) 10.1038/nprot.2008.22
38. Aerts H.J.W.L., Dubois L., Perk L., Vermaelen P., van Dongen G.A.M.S., Wouters B.G., et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50 (2009) 123-131
39. Shure K., and Deutsch M. Radiations from zirconium89. Phys Rev 82 (1951) 122
40. 89Zr reaction. Phys Lett 15 (1965) 155-157
41. Mustafa M.G., West Jr. H.I., O'Brien H., Lanier R.G., Benhamou M., and Tamura T. Measurements and a direct-reaction-plus-Hauser-Feshbach analysis of 89Y(p,n)89Zr, 89Y(p,2n)88Zr, and 89Y(p,pn)88Y reactions up to 40 MeV. Phys Rev C 38 (1988) 1624-1637
42. Bard A.J., Parsons R., and Jordan J. Standard Potentials in Aqueous Solutions, IUPAC (1985), Marcel Dekker, New York, USA
43. Kobayashi T., Sasaki T., Takagi I., and Moriyama H. Zirconium solubility in ternary aqueous system of Zr(IV)-OH-carboxylates. J Nucl Science Tech (Tokyo, Japan) 46 (2009) 142-148
44. Sasaki T., Kobayashi T., Takagi I., and Moriyama H. Hydrolysis constant and coordination geometry of zirconium(IV). J Nucl Science Tech (Tokyo, Japan) 45 (2008) 735-739
45. Kobayashi T., Sasaki T., Takagi I., and Moriyama H. Solubility of zirconium(IV) hydrous oxides. J Nucl Science Tech (Tokyo, Japan) 44 (2007) 90-94
46. 64Cu using a biomedical cyclotron. Nucl Med Biol 24 (1997) 35-43
47. Verel I., Visser Gerard W.M., and van Dongen Guus A. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 46 Suppl 1 (2005) 164S-171S